Table 1. Clinical trials of GLP-1 agonists.

Drugs	Conclusions	Phase	References
Dulaglutide	Improvement in patients with type 2 diabetes and MASLD	\	114
Efinopegdutide	Improvement of MASH and MASLD	Phase II	107
Exenatide	Improvement in patients with type 2 diabetes and MASLD	\	115
Liraglutide	Improvement of MASH and MASLD	Phase II/III	116–118
	Improvement in patients with type 2 diabetes and MASLD	Phase IV	119
	No improvement in patients with type 2 diabetes and MASLD	Phase IV	120
Semaglutide	Improvement of MASH but not liver fibrosis	Phase I/II	121,122
	Improvement of health-related quality of life in patients with MASH and liver fibrosis	Phase II	103

MASLD, metabolic dysfunction-associated steatotic liver disease; MASH, metabolic dysfunction-associated steatohepatitis.